Fact based stock research
Zur Rose Group (SWX:ROSE)

CH0042615283

Zur Rose Group stock research in summary

zurrosegroup.com


Zur Rose Group shares are more expensive than other comparable stocks. They are poor value, are riskily financed, and show below average growth. We recommend evaluating whether the future of the company Zur Rose Group is really as positive as the high price of the shares suggests. If you come to the conclusion that the future for this company is only average, that could be a reason to sell this share.


Latest Obermatt Ranks


Country Switzerland
Industry Drug Retail
Index SPI
Size class Large

June 2, 2022. Stock data may be delayed. Login to get the most recent research.


Achievements

Gold Winner CEO


Stock analysis by the purely financial fact-based Obermatt Method for the investment strategies Value, Growth and Safety for Zur Rose Group from June 2, 2022.

We invest in our stock tips ourselves and openly publish the returns of our portfolio. That's how much we believe in our stock research. Subscribe to the top 10 stocks for 100 markets conveniently by e-mail.